NEWEST VIDEO
Current Advances in Closed Loop Stimulation
Dr. Cory Hunter, President of NANS, presents an in-depth overview of closed-loop spinal cord stimulation (SCS) and the breakthrough potential of ECAP-controlled therapy. He contrasts traditional open-loop systems with real-time, adaptive stimulation that adjusts automatically to patient movement and physiology. Dr. Hunter highlights the EVOKE study’s durable, long-term results and explains how ECAPs may serve as predictive biomarkers, allowing for trial-less implantation and objective pain assessment. He emphasizes the clinical implications for improving outcomes, reducing trial failure, and enhancing patient trust. This presentation signals a new era in neuromodulation and the emerging role of "electroceuticals" in pain medicine.
Watch Now
Watch Now
NEWEST VIDEOS
This panel brings together Chief Medical Officers (CMOs) from both startups and large medtech companies to discuss their roles, experiences, and advice for physicians considering a similar career path. Each CMO shares insights on transitioning from clinical practice to industry, the importance of advocacy, research, and ROI in decision-making, and how their work now shapes patient care on a broader scale. They emphasize that becoming a CMO requires reputation, leadership, and a deep understanding of medicine, innovation, and business. Their advice is clear: follow your passion, build expertise, and don’t pursue the title—pursue the impact.
Watch Now
Watch Video
Device Company CMO Panel: Guiding Physicians into Working in the Device Industry
NEWEST VIDEO
Does Size Matter In Neuromodulation
This presentation explores the multifaceted role of size in neuromodulation, from electrode spacing and lead configurations to IPG dimensions, waveform characteristics, and energy delivery. Dr. Valimahomed discusses how different lead lengths, spacing, and configurations impact stimulation coverage and efficacy—particularly in spinal cord and peripheral nerve stimulation. He also analyzes how IPG size affects patient comfort, pocket pain, infection risk, and therapy adoption. Future-forward technologies like injectable and bioresorbable systems, AI-based programming, and neural dose optimization offer promising paths to miniaturization and precision. Ultimately, size matters—but contextually, depending on anatomical targets, clinical goals, and device trade-offs.
Watch Now
Watch Now
Watch Now
NEWEST VIDEO
Watch Now
Neuromodulation for Peripheral Neuropathy vs Mononeuropathy
In this insightful lecture, Dr. Leonardo Kapural reflects on 13 years of contributions to the Mediterranean Pain Forum and presents cutting-edge advancements in neuromodulation. Highlighting data from multiple studies, including magnetic and high-frequency peripheral nerve stimulation, the talk explores non-invasive alternatives to medication for neuropathic and diabetic pain, mononeuropathy, and post-amputation pain. With comparisons to traditional drugs like gabapentin, the speaker emphasizes the greater efficacy and patient satisfaction of neuromodulation. He also traces the evolution of techniques from invasive surgical placements to modern ultrasound-guided approaches and compact external stimulators, calling for earlier adoption of neuromodulation in pain treatment algorithms.
Neuromodulation for Visceral Pain
Dr. Andrew Kaufman presents a comprehensive review of spinal cord stimulation (SCS) for visceral pain, including anginal, abdominal, pancreatic, and pelvic pain. He discusses the complexity of visceral pain pathways and the challenges in diagnosis and treatment. Highlighting key studies—including those using high-frequency (10 kHz) and traditional SCS—Dr. Kaufman showcases improvements in pain relief, opioid reduction, and quality of life. However, he emphasizes the variability in outcomes, the need for better patient selection, and the lack of robust randomized studies. A recent sham-controlled trial even questions efficacy for chronic pancreatitis, reinforcing the importance of refining protocols.
Watch Now
NEWEST VIDEO
Watch Now
Watch Now
Dr. Cory Hunter, President of NANS, presents an in-depth overview of closed-loop spinal cord stimulation (SCS) and the breakthrough potential of ECAP-controlled therapy. He contrasts traditional open-loop systems with real-time, adaptive stimulation that adjusts automatically to patient movement and physiology. Dr. Hunter highlights the EVOKE study’s durable, long-term results and explains how ECAPs may serve as predictive biomarkers, allowing for trial-less implantation and objective pain assessment. He emphasizes the clinical implications for improving outcomes, reducing trial failure, and enhancing patient trust. This presentation signals a new era in neuromodulation and the emerging role of "electroceuticals" in pain medicine.
Current Advances in Closed Loop Stimulation
Watch Now
Device Company CMO Panel: Guiding Physicians into Working in the Device Industry
This panel brings together Chief Medical Officers (CMOs) from both startups and large medtech companies to discuss their roles, experiences, and advice for physicians considering a similar career path. Each CMO shares insights on transitioning from clinical practice to industry, the importance of advocacy, research, and ROI in decision-making, and how their work now shapes patient care on a broader scale. They emphasize that becoming a CMO requires reputation, leadership, and a deep understanding of medicine, innovation, and business. Their advice is clear: follow your passion, build expertise, and don’t pursue the title—pursue the impact.
Watch Now
This presentation explores the multifaceted role of size in neuromodulation, from electrode spacing and lead configurations to IPG dimensions, waveform characteristics, and energy delivery. Dr. Valimahomed discusses how different lead lengths, spacing, and configurations impact stimulation coverage and efficacy—particularly in spinal cord and peripheral nerve stimulation. He also analyzes how IPG size affects patient comfort, pocket pain, infection risk, and therapy adoption. Future-forward technologies like injectable and bioresorbable systems, AI-based programming, and neural dose optimization offer promising paths to miniaturization and precision. Ultimately, size matters—but contextually, depending on anatomical targets, clinical goals, and device trade-offs.
Does Size Matter In Neuromodulation
Watch Now
In this insightful lecture, Dr. Leonardo Kapural reflects on 13 years of contributions to the Mediterranean Pain Forum and presents cutting-edge advancements in neuromodulation. Highlighting data from multiple studies, including magnetic and high-frequency peripheral nerve stimulation, the talk explores non-invasive alternatives to medication for neuropathic and diabetic pain, mononeuropathy, and post-amputation pain. With comparisons to traditional drugs like gabapentin, the speaker emphasizes the greater efficacy and patient satisfaction of neuromodulation. He also traces the evolution of techniques from invasive surgical placements to modern ultrasound-guided approaches and compact external stimulators, calling for earlier adoption of neuromodulation in pain treatment algorithms.
Neuromodulation for Peripheral Neuropathy vs Mononeuropathy Watch Now
Dr. Andrew Kaufman presents a comprehensive review of spinal cord stimulation (SCS) for visceral pain, including anginal, abdominal, pancreatic, and pelvic pain. He discusses the complexity of visceral pain pathways and the challenges in diagnosis and treatment. Highlighting key studies—including those using high-frequency (10 kHz) and traditional SCS—Dr. Kaufman showcases improvements in pain relief, opioid reduction, and quality of life. However, he emphasizes the variability in outcomes, the need for better patient selection, and the lack of robust randomized studies. A recent sham-controlled trial even questions efficacy for chronic pancreatitis, reinforcing the importance of refining protocols.
Neuromodulation for Visceral Pain
